Belite Bio Sets Price for $350 Million Underwritten Public Offering of American Depositary Shares

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: Dec 01 2025

0mins

Source: Globenewswire

Public Offering Announcement: Belite Bio, Inc. has priced an underwritten public offering of 2,272,727 American Depositary Shares at $154.00 each, aiming to raise approximately $350 million before expenses, with the closing expected around December 3, 2025.
Use of Proceeds: The funds from the offering will be allocated for commercialization preparation, pipeline development, and general corporate purposes.
Company Focus: Belite Bio is dedicated to developing novel therapeutics for degenerative retinal diseases, with its lead candidate, Tinlarebant, currently undergoing multiple clinical trials.
Forward-Looking Statements: The press release includes forward-looking statements regarding the offering's completion and the company's future plans, emphasizing that actual results may differ due to various factors.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.